Holen Sie sich die Stockscreener-App
0.41
6.04%
-0.028
Handel nachbörslich:
.40
-0.010
-2.44%
Schlusskurs vom Vortag:
$0.438
Offen:
$0.4983
24-Stunden-Volumen:
11.74M
Relative Volume:
14.96
Marktkapitalisierung:
$24.76M
Einnahmen:
$2.29M
Nettoeinkommen (Verlust:
$-18.63M
KGV:
-0.7297
EPS:
-0.5619
Netto-Cashflow:
$-19.32M
1W Leistung:
+14.77%
1M Leistung:
+1.12%
6M Leistung:
-58.45%
1J Leistung:
-60.43%
1-Tages-Spanne:
$0.376
$0.528
1-Wochen-Bereich:
$0.33
$0.528
52-Wochen-Spanne:
$0.3067
$1.11
Femasys Inc Stock (FEMY) Company Profile
Firmenname
Femasys Inc
Sektor
Telefon
770-500-3910
Adresse
3950 JOHNS CREEK COURT, SUWANEE
Compare FEMY vs ISRG, BDX, ALC, MDLN, RMD
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
FEMY
Femasys Inc
|
0.41 | 26.45M | 2.29M | -18.63M | -19.32M | -0.5619 |
ISRG
Intuitive Surgical Inc
|
436.42 | 155.16B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
147.75 | 40.68B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
67.69 | 33.06B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
36.16 | 31.30B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
208.10 | 30.18B | 5.54B | 1.52B | 1.74B | 10.37 |
Femasys Inc Stock (FEMY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-11-20 | Eingeleitet | Laidlaw | Buy |
Femasys Inc Aktie (FEMY) Neueste Nachrichten
Femasys Analyst Ratings and Price Targets | NASDAQ:FEMY - Benzinga
FEMY Technical Analysis | Trend, Signals & Chart Patterns | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Maintains Target Price $1.5 - Moomoo
Femasys Expands Fertility Care Portfolio in Europe with CE Mark Approval for FemHSG™ Catheter - Sahm
Femasys receives CE Mark approval for FemHSG fertility catheter - Investing.com UK
Femasys updates corporate presentation on women’s health portfolio - TipRanks
Maxim Group Maintains Femasys(FEMY.US) With Buy Rating, Cuts Target Price to $1.5 - Moomoo
Femasys posts updated corporate presentation detailing fertility and FemBloc commercialization plans - TradingView
Femasys (NASDAQ: FEMY) outlines FemaSeed fertility and FemBloc birth control strategy - Stock Titan
Femasys receives CE Mark approval for FemHSG fertility catheter By Investing.com - Investing.com South Africa
Lake Street Remains a Buy on Femasys (FEMY) - The Globe and Mail
Femasys Expands Fertility Care Portfolio In Europe With CE Mark Approval For Femhsg™ Catheter - TradingView
TradingKey - TradingKey
Femasys Reverse Stock Split May Not Prevent Nasdaq Delisting Risk, Observer Warns - The Globe and Mail
Femasys Inc. Announces Financial Results for Quarter Ending March 31, 2026 - geneonline.com
Femasys Inc. Q1 2026 Financials: Revenue Growth, Forward-Looking Statements, and Market Strategy - Minichart
Femasys Inc expected to post a loss of 9 cents a shareEarnings Preview - TradingView
FEMASYS INC 1Q 2026: Revenue $424.9K, Net income $328.6K, EPS $0— 10-Q Summary - TradingView
Non-cash gains lift Femasys (NASDAQ: FEMY) to Q1 profit amid cash strain - Stock Titan
Net income returns at Femasys (NASDAQ: FEMY) as Q1 2026 results filed - Stock Titan
Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - The Manila Times
Femasys starts birth-control trial as it expands fertility care - Stock Titan
Press Release: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - Moomoo
FEMY SEC FilingsFEMASYS INC 10-K, 10-Q, 8-K Forms - Stock Titan
FEMY | Femasys Inc. Common Stock Insider Trading - Quiver Quantitative
Femasys Inc.: Femasys Announces Financial Results for Quarter Ended March 31, 2026 and Provides Corporate Update - FinanzNachrichten.de
FEMY News | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys pushes fertility treatment into OB/GYN offices with first paid use - Stock Titan
Femasys Enables OB/GYNs to Deliver First-Line Fertility - GlobeNewswire
Femasys Enables OB/GYNs to Deliver First-Line Fertility Treatment with Initial Commercial Use of FemaSeed® Complete - Yahoo Finance
MSN Money - MSN
FEMY Earnings History & Surprises | EPS & Revenue Results | FEMASYS INC (NASDAQ:FEMY) - ChartMill
Femasys Shareholders Approve Reverse Split and Financing Plans - The Globe and Mail
Femasys Inc. (NASDAQ: FEMY) sets 2026 meeting, director and auditor votes - Stock Titan
[ARS] FEMASYS INC SEC Filing - Stock Titan
Femasys (NASDAQ: FEMY) wins approval for reverse split, high-dilution notes - Stock Titan
Femasys Stock Slides After Company Prices Public Offering At Discount: Retail’s Planning To Load Up - MSN
FEMY Stock Price, Quote & Chart | FEMASYS INC (NASDAQ:FEMY) - ChartMill
PMCB Stock Jumps 25% After Company Sells Stake In Femasys - MSN
Femasys Launches FemaSeed® Complete for OB/GYNs at ACOG 2026 - The Manila Times
Femasys aims to bring first-line fertility treatment into OB/GYN offices - Stock Titan
Femasys (FEMY) Stock Jumps on Deal (+0.71%) 2026-04-18Buy Signals - Xã Thanh Hà
Femasys partners with AMI Technologies for Israel market entry By Investing.com - Investing.com India
Femasys Drives International Growth with Israeli Market Entry for Fertility Portfolio - Sahm
Femasys (FEMY) Forms Partnership with AMI Technologies to Expand Fertility Portfolio - GuruFocus
Femasys partners with AMI Technologies for Israel market entry - Investing.com
Weekly Trades: Is Femasys Inc stock undervalued right now2026 Review & AI Enhanced Execution Alerts - baoquankhu1.vn
Is Femasys (FEMY) Stock Breaking Out | Price at $0.40, Up 0.76%Elite Trading Signals - UBND thành phố Hải Phòng
Finanzdaten der Femasys Inc-Aktie (FEMY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.38%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):